Search Results  for '4153.TWO'

Advanced Search

per page
  Report Title Date Provider Type Pgs Price

DIVA Laboratories Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

06 Feb 2016 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - DIVA Laboratories Ltd (4153-OT)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

09 Feb 2016 Thomson Reuters Stock Report 11 $25.00

Diva Laboratories Ltd: Upgraded to Good

08 Feb 2016 Sadif Analytics Prime 3 $10.00

Wright Investors Service Comprehensive Report for Diva Laboratories Ltd

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

14 Jan 2016 Wright Reports 54 $75.00

Diva Laboratories Ltd: Upgraded to Above Average

03 Jun 2015 Sadif Analytics Prime 3 $10.00

鈺緯 (4153):子公司富動2015年營運大幅低於預期

展望2015年,元富預估鈺緯營收15億元,YOY +65%,成長動能來自(1) 3Q14開始供應Roche旗下的醫療系統廠Ventana,(2)1Q15併購的子公司富動,(3)新客戶美國醫材通路商;鈺緯並持續進行代理轉直接銷售,且切入高毛利的顯示器應...

21 May 2015 MasterLink Securities Corporation 5 $35.00

Diva Laboratories Ltd: Downgraded to Average

22 Jan 2015 Sadif Analytics Prime 3 $10.00

Is The Recovery in Diva Laboratories Ltd Too Much, Too Soon?

08 Jan 2015 Sadif Analytics Prime 12 $25.00

Diva Laboratories (4153 TT); Medical Monitor Maker with Strong Growth Potential

Our sales forecast for 2015 is NT$1.1bn, +21% YoY; after the merge, we expect FY15 sales to grow to 1.6bn, +77% YoY, and EPS ...

14 Dec 2014 MasterLink Securities Corporation 6 $58.00

鈺緯 (4153):進入大幅成長階段的專業醫療顯示器廠商

元富預估2015年鈺緯母公司營收11億元,YOY +21%,合併富動後營收16億元,YOY +77%;整體毛利率提升1.8%至32.6%,EPS 7.10元;我們觀察醫材本益比約14~21倍(2015年),而醫療顯示器為藍海市場,且醫療顯示器訂單穩定...

10 Dec 2014 MasterLink Securities Corporation 5 $35.00